Seres therapeutics reports second quarter 2021 financial results and provides business updates

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome company developing a novel class of multifunctional bacterial therapeutics designed to functionally interact with host cells and tissues to treat disease, today reported second quarter 2021 financial results and provided business updates. “we have made strong progress advancing ser-109, which we expect will become the first-ever fda-approved microbiome therapeutic. we are nearing target enrollment i
MCRB Ratings Summary
MCRB Quant Ranking